

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)



(10) International Publication Number
WO 2021/219731 A3

(51) International Patent Classification:

C07D 487/04 (2006.01) A61K 31/519 (2006.01)
C07D 498/18 (2006.01) A61K 31/529 (2006.01)
A61P 35/00 (2006.01)

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2021/061151

(22) International Filing Date:

28 April 2021 (28.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20171745.1 28 April 2020 (28.04.2020) EP

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(71) Applicant: **IOMX THERAPEUTICS AG** [DE/DE];
Fraunhoferstrasse 13, 82152 Martinsried (DE).

(88) Date of publication of the international search report:

09 December 2021 (09.12.2021)

(72) Inventors: **SENNHENN, Peter**; c/o iOmx Therapeutics AG Fraunhoferstrasse 13, 82152 Martinsried (DE). **LOFERER, Hannes**; c/o iOmx Therapeutics AG Fraunhoferstrasse 13, 82152 Martinsried (DE). **BANCROFT, David**; c/o iOmx Therapeutics AG Fraunhoferstrasse 13, 82152 Martinsried (DE). **KLUGE, Art**; c/o iOmx Therapeutics AG Fraunhoferstrasse 13, 82152 Martinsried (DE).

(74) Agent: **KUTTENKEULER, David**; Boehmert & Boehmert Anwaltspartnerschaft mbB, Pettenkoferstrasse 22, 80336 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: BICYCLIC KINASE INHIBITORS AND USES THEREOF

(57) Abstract: The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family, CSF1R, HCK, TEK-family, BRK, ABL, KIT and/or their mutants. Although structurally similar to other bicyclic kinase inhibitors, the kinase inhibitors of the invention are distinctive; possessing a particular class of heterocyclic moiety. Such kinase inhibitors can display one or more certain properties distinct to their structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally related kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions of the invention may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.



WO 2021/219731 A3